Pacira BioSciences, Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Pacira BioSciences, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Pacira BioSciences, Inc. or its management. Pacira BioSciences, Inc. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
Countdown toNOPAIN Act:
Days
ASP+6% reimbursement for EXPAREL effective January 1, 2025, when billing with code J0666 across all outpatient surgical settings
Effective January 1, 2025
NOPAIN Act provides expanded reimbursement for EXPAREL® (bupivacaine liposome injectable suspension)1
ASP+6% CMS reimbursement when billing EXPAREL with new code J0666 across outpatient settings2,3*
* For dates of service prior to January 1, 2025, Medicare reimbursement is available in ASCs when billing with C9290. For commercial or Medicare Advantage plans, please confirm with the individual payer.3
ASP+6% = reimbursement of 106% of the average sales price.
ASC, ambulatory surgical center; CMS, Centers for Medicare & Medicaid Services; NOPAIN, Non-Opioids Prevent Addiction in the Nation.
References: 1. Consolidated Appropriations Act 2023. Accessed October 30, 2024. https://www.congress.gov/117/bills/hr2617/BILLS-117hr2617enr.pdf; 2. CMS.gov. Medicare part B drug average sales price. Updated April 2, 2024. October 30, 2024. https://www.cms.gov/medicare/payment/fee-for-service-providers/part-b-drugs/average-drug-sales-price; 3. CMS.gov. Published October 10, 2024. Accessed October 30, 2024. https://www.cms.gov/files/document/2024-hcpcs-application-summary-quarter-3-2024-drugs-and-biologicals-posted-10-02-2024.pdf
